Dr. Agarwal's Health Care Limited announced the cessation of Sanjay Anand as an Independent Director effective September 29, 2026. The departure follows the completion of his second term of five consecutive years, in compliance with statutory tenure limits.

The company filed a disclosure with BSE and NSE citing Section 149(11) of the Companies Act, 2013 and Regulation 25 of the SEBI Listing Regulations. These provisions mandate that an independent director cannot serve more than two consecutive terms. Anand’s tenure concluded at the close of business hours on the filing date.

Committee reconstitution

Following Anand’s exit, Dr. Agarwal's Health Care Limited revised the composition of its Board committees to ensure continued compliance with governance norms. The Audit Committee, Nomination and Remuneration Committee, Stakeholders Relationship Committee, Corporate Social Responsibility Committee, and Risk Management Committee have been reconstituted with new chairpersons and members.

The updated committee structures are detailed below:

Governance implications

The reconstitution maintains a majority of independent directors across key oversight committees, including Audit and Risk Management. This structure aligns with SEBI requirements for listed entities to ensure robust internal controls and stakeholder protection. The board expressed gratitude for Anand’s guidance during his tenure.

Dr. Agarwal's Health Care shareholders approved all seven resolutions at its 16th annual general meeting, including the adoption of FY26 financial statements and remuneration revisions for top executives. The virtual meeting, held on September 21, 2026, saw unanimous promoter support and overwhelming public backing for most agenda items.

The company reported a total shareholder base of 42,656 as of the record date, September 15, 2026. Of these, 30,13,60,021 votes were polled across the resolutions, representing approximately 95% of outstanding shares. Mr. Subramanian Chandrasekar served as the independent scrutinizer, confirming that all resolutions passed with the requisite majority.

Resolution Outcomes

The AGM covered governance appointments, auditor ratification, and executive compensation changes. While promoter interests voted uniformly in favour of all proposals, public institutional investors showed varying levels of dissent, particularly regarding the reappointment of Non-Executive Director Mr. Ankur Nand Thadani.

Voting Participation

Remote e-voting was conducted from September 17 to September 20, 2026. The promoter group, holding 10,25,04,118 shares, voted 100% in favour of every resolution. Public institutional shareholders, holding 20,70,23,062 shares, participated actively, polling over 95% of their holdings.

The only resolution facing notable dissent was Item 3, the reappointment of Mr. Ankur Nand Thadani. Public institutional investors cast 3,70,38,008 votes against this proposal, resulting in a 12.30% dissent rate among total votes polled. However, strong support from non-institutional public shareholders ensured the resolution passed with an overall 87.70% approval.

All other resolutions received near-unanimous support from public shareholders, with dissent rates below 0.2% for financial adoption and auditor appointments.